Index additions put Haemonetics in focus
Haemonetics (HAE) has attracted fresh attention after being added to multiple Russell value and small cap benchmarks, a technical catalyst that often brings incremental demand from index tracking funds.
For existing and prospective shareholders, these inclusions raise practical questions about how benchmark driven flows might interact with Haemonetics' fundamentals, recent share performance and the timing of upcoming events on the company’s calendar.
See our latest analysis for Haemonetics.
Haemonetics' latest share price of US$76.19 comes after a 32.9% 90 day share price return, while the 1 year total shareholder return is 0.9% and the 5 year total shareholder return is 26.3%. This suggests momentum has recently picked up around the time of the Russell index additions and ahead of the upcoming first quarter fiscal 2027 results announcement.
Given this renewed interest around Haemonetics, it can be useful to see what else investors are watching in related areas, especially companies using AI in healthcare, so take a look at 41 healthcare AI stocks
Haemonetics now appears in several value indices and the share price has climbed over the past quarter, so the key issue for you is whether a solid medical technology business is still being offered at an appealing valuation today.
Most Popular Narrative: 12.3% Undervalued
Haemonetics' most followed narrative points to a fair value of $86.90, above the last close at $76.19, and frames the recent index driven interest against longer term earnings assumptions.
Enterprise-wide portfolio transformation highlighted by the divestiture of low-margin businesses, disciplined capital deployment, and ongoing investment in automation and digital solutions is driving substantial gross and operating margin expansion (guidance of 26 to 27% for FY26) and is likely to support further improvements in net margins and free cash flow conversion.
Read the complete narrative. Read the complete narrative.
Want to know what earnings path and margin rebuild sit behind that valuation gap? The narrative leans heavily on compound profit growth assumptions and a higher future earnings multiple. Curious how those moving parts connect to the $86.90 figure?
Result: Fair Value of $86.90 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Haemonetics' reliance on a small set of U.S. focused products, along with ongoing execution questions around VASCADE, means that competitive or regulatory setbacks could quickly challenge that undervalued story.
Find out about the key risks to this Haemonetics narrative.
Next Steps
If the mixed sentiment around Haemonetics has you weighing both upside and risk, act while the data is fresh and shape your own view with 2 key rewards and 3 important warning signs
Looking for more stock ideas beyond Haemonetics?
If Haemonetics has sharpened your focus on where capital goes next, do not stop here. Use the Simply Wall Street Screener to uncover more targeted opportunities.
- Target steadier portfolio anchors by scanning 76 resilient stocks with low risk scores that may help smooth out the bumps when markets get choppy.
- Hunt for potential value opportunities by reviewing 44 high quality undervalued stocks that combine quality fundamentals with prices that may not fully reflect their financial profile.
- Spot future standouts early by checking the screener containing 19 high quality undiscovered gems before they sit firmly on everyone else's radar.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com